除了类风湿病:重新考虑在生物时代对克罗恩病的甲状腺
1Division of Gastroenterology and Hepatology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam-si 13496, South Korea.
World journal of gastroenterology
|January 19, 2026
概括
尽管甲托雷克萨特 (MTX) 是安全的,但它在克罗恩病中未得到充分利用. 法国胃肠道学家认为MTX是一种次要选择,但其作为特定高风险患者的一线治疗的潜力越来越得到认可.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 免疫调节剂,如甲醇 (MTX) 历来是克罗恩病 (CD) 的第一线治疗药物.
- 生物学家已经将免疫调节剂的使用转移到辅助疗法,通常使用抗TNF药物.
- 由于担心氨酸的安全性,人们重新对MTX产生了兴趣,MTX具有良好的安全性.
研究的目的:
- 调查法国胃肠病学家当前的MTX处方行为.
- 了解MTX在克罗恩病管理中的作用和障碍.
- 倡导MTX作为特定患者群体的潜在一线治疗.
主要方法:
- 进行了一项全国性的法国胃肠道病学家调查.
- 该调查评估了当前的做法,看法和使用MTX在克罗恩病中的原因.
- 来自Bonnaud等人调查的数据. 在世界胃肠病学杂志上进行了分析.
主要成果:
- 71%的胃肠科医生使用MTX,主要是通过皮下注射.
- 在 thiopurines 之后,MTX 主要被视为次要选择.
- 使用不足归因于临床惯性和缺乏指导,而不是有效性或安全性问题.
结论:
- 尽管有积极的看法,但MTX在克罗恩病管理中仍未得到充分利用.
- 对于MTX使用的障碍似乎是可以修改的,这表明可能会增加采用.
- 需要更明确的指导方针和教育来重新定位MTX,作为对已定义的高风险克罗恩病患者群体的战略第一线选择.
相关概念视频
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
780
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
780
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
897
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
897
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
703
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
703
01:29Inflammatory Bowel Disease IV: Pharmacological Management
1.1K
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
1.1K
01:29Therapeutic Drug Monitoring: Affecting Factors
438
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
438
01:25Inflammatory Bowel Disease III: Crohn's Disease
69
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
69